Search research articles
Contact Us
Filters
Showing results (141-150 of 252) with videos related to
Page
of 26
Sort By:
Immunity
|
December 7, 2007
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells
Elke Pogge von Strandmann, Venkateswara Rao Simhadri, Bastian von Tresckow, et al.
The Lancet. Oncology
|
November 22, 2012
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
Norbert Schmitz, Maike Nickelsen, Marita Ziepert, et al.
Hemasphere
|
June 5, 2024
Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma
Berit Müller-Meinhard, Nicole Seifert, Johanna Grund, et al.
British Journal of Haematology
|
March 15, 2023
Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma
Johanna Grund, Katharina Iben, Sarah Reinke, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 17, 2024
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
Johannes Rosenbrock, Helen Kaul, Michael Oertel, et al.
International Journal of Environmental Research and Public Health
|
March 19, 2020
Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
Allan Relecom, Massimo Federico, Joseph M Connors, et al.
British Journal of Haematology
|
July 26, 2022
Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma
Sylvia Hartmann, Ahmad Sajad Soltani, Katrin Bankov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2005
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial
Thomas Elter, Peter Borchmann, Holger Schulz, et al.
JAMA Oncology
|
February 5, 2026
BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma
Justin Ferdinandus, Horst Müller, Janina Jablonski, et al.
Leukemia
|
August 19, 2021
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
Carla Damaschin, Helen Goergen, Stefanie Kreissl, et al.
Page
of 26
Search research articles
Search
Showing results (141-150 of 252) with videos related to
Sort By:
Page
of 26
Immunity
|
December 7, 2007
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells
Elke Pogge von Strandmann, Venkateswara Rao Simhadri, Bastian von Tresckow, et al.
The Lancet. Oncology
|
November 22, 2012
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
Norbert Schmitz, Maike Nickelsen, Marita Ziepert, et al.
Hemasphere
|
June 5, 2024
Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma
Berit Müller-Meinhard, Nicole Seifert, Johanna Grund, et al.
British Journal of Haematology
|
March 15, 2023
Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma
Johanna Grund, Katharina Iben, Sarah Reinke, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 17, 2024
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
Johannes Rosenbrock, Helen Kaul, Michael Oertel, et al.
International Journal of Environmental Research and Public Health
|
March 19, 2020
Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
Allan Relecom, Massimo Federico, Joseph M Connors, et al.
British Journal of Haematology
|
July 26, 2022
Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma
Sylvia Hartmann, Ahmad Sajad Soltani, Katrin Bankov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2005
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial
Thomas Elter, Peter Borchmann, Holger Schulz, et al.
JAMA Oncology
|
February 5, 2026
BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma
Justin Ferdinandus, Horst Müller, Janina Jablonski, et al.
Leukemia
|
August 19, 2021
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
Carla Damaschin, Helen Goergen, Stefanie Kreissl, et al.
Page
of 26